Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immuron Limited
  6. Summary
    IMC   AU000000IMC7

IMMURON LIMITED

(IMC)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 09/24
0.14 AUD   -12.50%
06:12aIMMURON : Director resignation (Form 6-K)
PU
09/23IMMURON : Director resignation
AQ
09/23IMMURON : planned Acquisition of R&D Vaccine Company
AQ
 SummaryChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
05/21/2021 05/24/2021 05/25/2021 05/26/2021 09/24/2021 Date
0.165 0.165 0.16 0.16 0.14 Last
743068 417232 425695 428354 2114998 Volume
-2.94% 0.00% -3.03% 0.00% -12.50% Change
Estimated financial data (e)
Sales 2020 2,52 M 1,83 M 1,83 M
Net income 2020 -2,93 M -2,12 M -2,12 M
Net cash position 2020 3,19 M 2,31 M 2,31 M
P/E ratio 2020 -15,7x
Yield 2020 -
Sales 2021 0,15 M 0,11 M 0,11 M
Net income 2021 -8,38 M -6,09 M -6,09 M
Net cash position 2021 25,0 M 18,2 M 18,2 M
P/E ratio 2021 -4,22x
Yield 2021 -
Capitalization 31,8 M 23,1 M 23,1 M
EV / Sales 2020 17,1x
EV / Sales 2021 77,7x
Nbr of Employees -
Free-Float 82,0%
More Financials
Company
Immuron Limited is an Australia-based biopharmaceutical company. The Company is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The Company operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States.... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
All news about IMMURON LIMITED
06:12aIMMURON : Director resignation (Form 6-K)
PU
09/23IMMURON : Director resignation
AQ
09/23IMMURON : planned Acquisition of R&D Vaccine Company
AQ
09/23IMMURON : planned Acquisition of R&D Vaccine Company (Form 6-K)
PU
08/31IMMURON : Loss from ordinary activities after tax attributable to members (Form 6-K)
PU
08/31Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
06/08IMMURON : Market Update (Form 6-K)
PU
05/14IMMURON : Appointment of Chief Medical Officer with preliminary focus on COVID-19 (Form 6-..
PU
05/14IMMURON : Investigates Antiviral Properties of IMM124E Formulation
MT
05/13IMMURON : Says IMM124E Product May Offer New Way of Preventing COVID-19 Infection
MT
05/13Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program
CI
05/13IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
GL
05/12Immuron Limited Appoints Dan Peres as Chief Medical Officer
CI
01/11IMMURON : to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
AQ
2020Immuron SARS-CoV-2 Research Agreement with Monash University
GL
More news
News in other languages on IMMURON LIMITED

- No features available -

More news
Chart IMMURON LIMITED
Duration : Period :
Immuron Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Jerry Kanellos Chief Executive & Operating Officer
Phillip Allen Hains Chief Financial Officer & Secretary
Roger Aston Independent Non-Executive Chairman
Dan Peres Chief Medical Officer
Daniel Jude Pollock Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMURON LIMITED-39.13%27
CSL LIMITED10.18%104 042
WUXI BIOLOGICS (CAYMAN) INC.14.59%65 634
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 879
BIOGEN INC.18.16%43 697
ALEXION PHARMACEUTICALS, INC.0.00%40 336